Department of Psychology and Neuroscience, University of Colorado Boulder, 345 UCB Muenzinger, Boulder, CO, 80309-0345, USA.
Division of Cancer Prevention and Control, University of Colorado Cancer Center, Aurora, CO, USA.
Ann Behav Med. 2022 Aug 2;56(8):856-871. doi: 10.1093/abm/kaab118.
Oral anti-cancer treatments such as adjuvant endocrine therapies (AET) for breast cancer survivors are commonly used but adherence is a challenge. Few low-touch, scalable interventions exist to increase ET adherence.
To evaluate the acceptability, feasibility, and initial efficacy of a low-touch, remotely-delivered values plus AET education intervention (REACH) to promote AET adherence.
A mixed-methods trial randomized 88 breast cancer survivors 1:1 to REACH or Education alone. Wisepill real-time electronic adherence monitoring tracked monthly AET adherence during a 1-month baseline through 6-month follow-up (FU) (primary outcome). Patient-reported outcomes were evaluated through 3- and 6-month FU (secondary). Multiple indices of intervention feasibility and acceptability were evaluated. Qualitative exit interviews (n = 38) further assessed participants' perceptions of feasibility/acceptability and recommendations for intervention adaptation.
The trial showed strong feasibility and acceptability, with an eligible-to-enrolled rate of 85%, 100% completion of the main intervention sessions, and "good" intervention satisfaction ratings on average. For Wisepill-assessed AET adherence, REACH outperformed Education for Month 1 of FU (p = .027) and not thereafter. Participants in REACH maintained high adherence until Month 4 of FU, whereas in Education, adherence declined significantly in Month 1. Conditions did not differ in self-reported adherence, positive affective attitudes, future intentions, or necessity beliefs. REACH trended toward less negative AET attitudes than Education at 3-month FU (p = .057) reflecting improvement in REACH (p = .004) but not Education (p = .809). Exploratory moderator analyses showed that average to highly positive baseline AET affective attitudes and oncologist-patient communication each predicted higher adherence following REACH than Education; low levels did not. Participants identified recommendations to strengthen the interventions.
REACH, a low-touch values intervention, showed good feasibility and acceptability, and initial promise in improving objectively-assessed AET adherence among breast cancer survivors (relative to education alone). Future research should target improving REACH's tailoring and endurance.
口服抗癌治疗,如乳腺癌幸存者的辅助内分泌治疗(AET),通常被使用,但坚持治疗是一个挑战。很少有低接触、可扩展的干预措施来提高 ET 依从性。
评估一种低接触、远程提供价值观加 AET 教育干预(REACH)以促进 AET 依从性的可接受性、可行性和初步疗效。
一项混合方法试验将 88 名乳腺癌幸存者随机分为 1:1 的 REACH 或单独教育组。Wisepill 实时电子依从性监测在 1 个月的基线期间跟踪每月 AET 的依从性,直到 6 个月的随访(FU)(主要结局)。通过 3 个月和 6 个月的 FU 评估患者报告的结果(次要结局)。评估了多项干预措施的可行性和可接受性指标。定性退出访谈(n=38)进一步评估了参与者对可行性/可接受性的看法,并对干预措施的调整提出了建议。
试验显示出很强的可行性和可接受性,合格入组率为 85%,主要干预课程 100%完成,平均干预满意度“良好”。对于 Wisepill 评估的 AET 依从性,REACH 在 FU 的第 1 个月优于教育组(p=0.027),此后则不然。REACH 组的参与者在 FU 的第 4 个月保持了高依从性,而在教育组,依从性在第 1 个月显著下降。两种情况下,自我报告的依从性、积极的情感态度、未来的意图和必要性信念均无差异。REACH 在 3 个月 FU 时的 AET 态度呈负向趋势低于教育组(p=0.057),反映了 REACH 的改善(p=0.004),而不是教育组(p=0.809)。探索性调节因素分析表明,平均至高度积极的 AET 情感态度和肿瘤医生与患者的沟通均预测在 REACH 后比教育组更高的依从性;低水平则不然。参与者提出了加强干预措施的建议。
REACH,一种低接触的价值观干预措施,表现出良好的可行性和可接受性,并且在提高乳腺癌幸存者的客观评估 AET 依从性方面有初步的希望(与单独教育相比)。未来的研究应致力于提高 REACH 的针对性和耐久性。